Preclinical Evaluation of Nitroxide-Functionalised Ciprofloxacin as a Novel Antibiofilm Drug Hybrid for Urinary Tract Infections

Urinary tract infections (UTIs) are the second most common bacterial infection with high recurrence rates and can involve biofilm formation on patient catheters. Biofilms are inherently tolerant to antimicrobials, making them difficult to eradicate. Many antibiofilm agents alone do not have bacteric...

Full description

Bibliographic Details
Main Authors: Sophia Hawas, Jilong Qin, Sandra Wiedbrauk, Kathryn Fairfull-Smith, Makrina Totsika
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/12/10/1479
_version_ 1797574979331555328
author Sophia Hawas
Jilong Qin
Sandra Wiedbrauk
Kathryn Fairfull-Smith
Makrina Totsika
author_facet Sophia Hawas
Jilong Qin
Sandra Wiedbrauk
Kathryn Fairfull-Smith
Makrina Totsika
author_sort Sophia Hawas
collection DOAJ
description Urinary tract infections (UTIs) are the second most common bacterial infection with high recurrence rates and can involve biofilm formation on patient catheters. Biofilms are inherently tolerant to antimicrobials, making them difficult to eradicate. Many antibiofilm agents alone do not have bactericidal activity; therefore, linking them to antibiotics is a promising antibiofilm strategy. However, many of these hybrid agents have not been tested in relevant preclinical settings, limiting their potential for clinical translation. Here, we evaluate a ciprofloxacin di-nitroxide hybrid (CDN11), previously reported to have antibiofilm activity against uropathogenic <i>Escherichia coli</i> (UPEC) strain UTI89 in vitro, as a potential UTI therapeutic using multiple preclinical models that reflect various aspects of UTI pathogenesis. We report improved in vitro activity over the parent drug ciprofloxacin against mature UTI89 biofilms formed inside polyethylene catheters. In bladder cell monolayers infected with UTI89, treatment with CDN11 afforded significant reduction in bacterial titers, including intracellular UPEC. Infected mouse bladders containing biofilm-like intracellular reservoirs of UPEC UTI89 showed decreased bacterial loads after ex vivo bladder treatment with CDN11. Activity for CDN11 was reported across different models of UTI, showcasing nitroxide–antibiotic hybridization as a promising antibiofilm approach. The pipeline we described here could be readily used in testing other new therapeutic compounds, fast-tracking the development of novel antibiofilm therapeutics.
first_indexed 2024-03-10T21:29:49Z
format Article
id doaj.art-da09728af84f4a31bf10fe61af743f6e
institution Directory Open Access Journal
issn 2079-6382
language English
last_indexed 2024-03-10T21:29:49Z
publishDate 2023-09-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj.art-da09728af84f4a31bf10fe61af743f6e2023-11-19T15:26:04ZengMDPI AGAntibiotics2079-63822023-09-011210147910.3390/antibiotics12101479Preclinical Evaluation of Nitroxide-Functionalised Ciprofloxacin as a Novel Antibiofilm Drug Hybrid for Urinary Tract InfectionsSophia Hawas0Jilong Qin1Sandra Wiedbrauk2Kathryn Fairfull-Smith3Makrina Totsika4Centre for Immunology and Infection Control, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4006, AustraliaCentre for Immunology and Infection Control, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4006, AustraliaSchool of Chemistry and Physics, Faculty of Science, Queensland University of Technology, Brisbane, QLD 4000, AustraliaSchool of Chemistry and Physics, Faculty of Science, Queensland University of Technology, Brisbane, QLD 4000, AustraliaCentre for Immunology and Infection Control, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4006, AustraliaUrinary tract infections (UTIs) are the second most common bacterial infection with high recurrence rates and can involve biofilm formation on patient catheters. Biofilms are inherently tolerant to antimicrobials, making them difficult to eradicate. Many antibiofilm agents alone do not have bactericidal activity; therefore, linking them to antibiotics is a promising antibiofilm strategy. However, many of these hybrid agents have not been tested in relevant preclinical settings, limiting their potential for clinical translation. Here, we evaluate a ciprofloxacin di-nitroxide hybrid (CDN11), previously reported to have antibiofilm activity against uropathogenic <i>Escherichia coli</i> (UPEC) strain UTI89 in vitro, as a potential UTI therapeutic using multiple preclinical models that reflect various aspects of UTI pathogenesis. We report improved in vitro activity over the parent drug ciprofloxacin against mature UTI89 biofilms formed inside polyethylene catheters. In bladder cell monolayers infected with UTI89, treatment with CDN11 afforded significant reduction in bacterial titers, including intracellular UPEC. Infected mouse bladders containing biofilm-like intracellular reservoirs of UPEC UTI89 showed decreased bacterial loads after ex vivo bladder treatment with CDN11. Activity for CDN11 was reported across different models of UTI, showcasing nitroxide–antibiotic hybridization as a promising antibiofilm approach. The pipeline we described here could be readily used in testing other new therapeutic compounds, fast-tracking the development of novel antibiofilm therapeutics.https://www.mdpi.com/2079-6382/12/10/1479bladderurinary tract infectionUPECbacterial biofilmscathetersnitroxides
spellingShingle Sophia Hawas
Jilong Qin
Sandra Wiedbrauk
Kathryn Fairfull-Smith
Makrina Totsika
Preclinical Evaluation of Nitroxide-Functionalised Ciprofloxacin as a Novel Antibiofilm Drug Hybrid for Urinary Tract Infections
Antibiotics
bladder
urinary tract infection
UPEC
bacterial biofilms
catheters
nitroxides
title Preclinical Evaluation of Nitroxide-Functionalised Ciprofloxacin as a Novel Antibiofilm Drug Hybrid for Urinary Tract Infections
title_full Preclinical Evaluation of Nitroxide-Functionalised Ciprofloxacin as a Novel Antibiofilm Drug Hybrid for Urinary Tract Infections
title_fullStr Preclinical Evaluation of Nitroxide-Functionalised Ciprofloxacin as a Novel Antibiofilm Drug Hybrid for Urinary Tract Infections
title_full_unstemmed Preclinical Evaluation of Nitroxide-Functionalised Ciprofloxacin as a Novel Antibiofilm Drug Hybrid for Urinary Tract Infections
title_short Preclinical Evaluation of Nitroxide-Functionalised Ciprofloxacin as a Novel Antibiofilm Drug Hybrid for Urinary Tract Infections
title_sort preclinical evaluation of nitroxide functionalised ciprofloxacin as a novel antibiofilm drug hybrid for urinary tract infections
topic bladder
urinary tract infection
UPEC
bacterial biofilms
catheters
nitroxides
url https://www.mdpi.com/2079-6382/12/10/1479
work_keys_str_mv AT sophiahawas preclinicalevaluationofnitroxidefunctionalisedciprofloxacinasanovelantibiofilmdrughybridforurinarytractinfections
AT jilongqin preclinicalevaluationofnitroxidefunctionalisedciprofloxacinasanovelantibiofilmdrughybridforurinarytractinfections
AT sandrawiedbrauk preclinicalevaluationofnitroxidefunctionalisedciprofloxacinasanovelantibiofilmdrughybridforurinarytractinfections
AT kathrynfairfullsmith preclinicalevaluationofnitroxidefunctionalisedciprofloxacinasanovelantibiofilmdrughybridforurinarytractinfections
AT makrinatotsika preclinicalevaluationofnitroxidefunctionalisedciprofloxacinasanovelantibiofilmdrughybridforurinarytractinfections